RE:RE:RE:ASCO relevance Genenan2004, welcome back! I remember you from the old Yahoo ONCY and ONCY v2 boards. You were always a voice of calm reason and you often brought valuable insight. If I remember correctly you were an MD or involved in biotech, or something to that effect. In any case I am pretty sure you are the same guy as from the old days since you write in the same thoughtful and informed style.
I was also a pretty engaged ONCY message board participant from around 2002 to 2013, but I then backed-off as my work life got busier and as I saw it would take significantly longer for ONC/Y to prove itself (if ever). I kept reading press releases and quarterly reports, but rarely message boards. I sold all my shares at one point when I expected a pull-back, but then bought them all back ( and more) at a lower price point. It certainly helped my average shareprice, but like most here I'm still considerably under water. As the shift in thinking took place from reolysin (pelareorep) as a cytotoxic to primarily an immuno-therapeutic agent my interest grew again. I was impressed by the calm focus of ONC/Y on this new direction and the consistent progress they were making.
So now we are here, partly through a long string of positive results over the past few years and hoping for strong supportive evidence from the maturing data of BRACELET-1. Hopefully enough evidence to lead us to a partnership or buyout and one or two registration studies in the near term.
We will have lots to chew on over the next few months. I welcome your input in digesting the news.